Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics

Abiraterone acetate (AA) has been proven effective for metastatic castration-resistant prostate cancer (mCRPC), and it has been proposed that adaptive AA may reduce toxicity and prolong time to progression, when compared to continuous AA. We developed a simple quantitative model of prostate-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Brady-Nicholls, Renee, Zhang, Jingsong, Zhang, Tian, Wang, Andrew Z., Butler, Robert, Gatenby, Robert A., Enderling, Heiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322456/
https://www.ncbi.nlm.nih.gov/pubmed/34298234
http://dx.doi.org/10.1016/j.neo.2021.06.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322456/
https://www.ncbi.nlm.nih.gov/pubmed/34298234
http://dx.doi.org/10.1016/j.neo.2021.06.013

Ejemplares similares